Mendelian Randomization Indicates Enhanced Lipid Control is Essential for Omega-3's Cardiovascular Protection

Jinhan **Yu**, MSc[1,#]; Chengjia **Li**, MSc[1,#]; Zipeng, **Liu**, PhD[2]; Yidan **Chen,** MPhil[1]; Yao **Lei**, MPhil[3]; Dingyang **Li**, MSc[1]; Wen **Ma**, PhD[4]; Yao **Wang**, PhD[5]; Yi **Yang**, MD, PhD[6]; Renzhi **Wang**, MD, PhD[1]; Yong-Fei **Wang**, PhD[1,*]

Author affiliations

1. School of Medicine, Warshel Institute for Computational Biology, The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
2. Clinical Data Center, Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China
3. Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
4. School Board of Decision Sciences, The Hang Seng University of Hong Kong, Hong Kong, China
5. Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
6. Department of Nephrology, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang, China

#These authors contributed equally.

*Correspondence to: Yong-Fei Wang (yfwang@cuhk.edu.cn)

Abstract

Importance: Omega-3 fatty acids are widely regarded as beneficial supplementation for preventing cardiovascular disease. However, the definitive role of omega-3 fatty acid in reducing cardiovascular risk remains inconclusive. It is crucial to elucidate their relationship for informed clinical guidance.

Objective: This study aims to examine the causal relationship between omega-3 fatty acids and cardiovascular disease.

Design: We employed five well-established mendelian randomization (MR) methods to investigate the causal association between omega-3 and cardiovascular events. Two large independent omega-3 GWAS (>110,000 participants each) were analyzed across 14 cardiovascular and metabolic phenotypes (>50,000 participants each). To understand the direct effect of omega-3 on coronary artery disease (CAD), multivariable MR (MVMR) model and mediation analysis were conducted. Summary-data-based MR (SMR) was further applied to identify circulating proteins associated with omega-3 levels.

Results: Genetically elevated omega-3 levels were found associated with increased cardiovascular risk across all MR methods, particularly for CAD (P_{median} = 2.65E-04), myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03). Higher genetically predicted omega-3 were significantly linked to elevated LDL-C (P_{median} = 2.50E-33) and its key component apolipoprotein B (P_{median} = 5.60E-08), while significantly reducing triglyceride levels (P_{median} = 4.16E-03). Notably, after adjusting for the genetic effect of LDL-C, omega-3 exhibited a protective effect on CAD ($\beta_{combined}$ = -0.025, $P_{combined}$ = 0.022), which was strengthened by adjusting for both LDL-C and triglycerides. Mediation analysis suggests that omega-3 is likely to increase CAD risk through raising LDL-C (P_{median} = 2.40E-12). Revisiting data from the STRENGTH and REDUCE-IT trials indicated that the cardiovascular benefits of omega-3 were closely related to the intensity of LDL-C lowering. Circulating proteins regulating lipid homeostasis, such as ANGPTL3 (P_{smr} = 1.22E-27) and PCSK9 (P_{smr} = 1.15E-21), were also found positively associated with omega-3 levels.

Conclusion and Relevance: Our results suggest that the cardiovascular

benefits of omega-3 fatty acids are context-dependent, showing protective

effects when lipids, particularly LDL-C, are well controlled. We hypothesize that

combining omega-3 supplementation with effective lipid-lowering therapy, such

as those targeting ANGPTL3 or PCSK9, may enhance the cardiovascular

benefits.

Introduction

Omega-3 fatty acids, a type of polyunsaturated fatty acids, have long been investigated for their potential protective effects on cardiovascular health. Retrospective studies have demonstrated that higher fish consumption and elevated circulating levels of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a reduced risk of cardiovascular events[1,2].

However, evidence from two landmark randomized clinical trials (RCTs) regarding the cardiovascular benefits of omega-3 fatty acids remains inconclusive. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT, n = 8,179; NCT01492361) reported that high-dose icosapent ethyl (a purified and stable EPA ethyl ester, 4g/d) significantly reduced major cardiovascular events by 25% in patients with hypertriglyceridemia over a median follow-up of 4.90 years[3]. However, concerns have been raised regarding the use of mineral oil as placebo. In contrast, the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH, n = 13,078; NCT02104817) trial found no significant cardiovascular benefit with omega-3 CA (a carboxylic acid formulation of EPA and DHA, 4g/d) compared to corn oil over a median follow-up of 42.0 months[4].

These conflicting RCT findings highlight the challenges in establishing a clear causal relationship between omega-3 fatty acids and cardiovascular outcomes. These inconsistencies may result from placebo selection, dosing regimens, study populations, and the difficulty of controlling numerous confounding factors in clinical research. Mendelian randomization (MR), which uses genetic variants as instrumental variables (IVs) for exposures (such as circulating omega-3 levels), addresses these challenges by leveraging the random allocation of genetic variants at conception. This approach provides a robust tool for causal inference that is less likely to be influenced by differences in factors such as age, sex, lifestyles, placebo selection, or dosing regimens[5,6].

To date, at least 16 MR methods have been developed, with key differences in
the selection of IVs, modeling, and techniques to control potential pleiotropy[7,8].
Among these, the inverse variance weighed (IVW) fixed-effects model remains
the most widely used method. However, due to its higher susceptibility to type
I error (false positive), MR-Egger[9], Weighted-mode[10], and MR-APSS[11] models
were also incorporated in this study. These methods have shown robust control
of type I errors and improved accuracy in estimating causal effects under
diverse conditions in both simulated and real-world data[8,12].

To ensure robust causal inference, we integrated data from two large
independent genome-wide association studies (GWAS) of circulating omega-
3[13,14] with genetic data on 14 cardiovascular and metabolic phenotypes, each
involving more than 50,000 participants (**Figure 1**). This study aims to
systematically examine the causal relationships between omega-3 fatty acids
and cardiovascular risk.

113　Methods

114　Study design and data sources

The full GWAS summary statistics used in this analysis were primarily obtained
from the GWAS Catalog[15], with detailed information provided in **Table S1**.
These GWAS studies were predominantly conducted in European populations.
To ensure adequate statistical power, we included only studies with at least
50,000 participants.

We collected two independent GWAS datasets for omega-3 measurement as
the exposure (**Figure 1**). The primary exposure dataset was derived from a
multi-cohort study, involving 136,016 participants[13], while the secondary
exposure dataset was sourced from the UK Biobank, including 115,006
individuals[14]. Notably, there was no sample overlap between these two
datasets, strengthening the validity of our findings. In addition, DHA
measurements from the UK Biobank (n = 115,006)[14] were also included as the
exposure. Age, sex, principal components and relevant study-specific
covariates have been adjusted in these studies.

We assessed a broad range of cardiovascular events. The primary
cardiovascular outcomes were coronary artery disease (CAD)[16,17], myocardial
infarction (n = 639,221)[18], heart failure (n = 977,323)[19], atrial fibrillation (n =
583,168)[20], stroke (n = 446.696)[21] and its ischemic subtype (n = 440328)[21]. Two
CAD GWAS datasets were analyzed: (i) a recent European meta-analysis with
181,522 cases and 1,165,690 controls[17], and (ii) the UK Biobank (34,541 cases
and 261,984 controls)[16]. We also examined type 2 diabetes (T2D, n =
659,316)[22] because of its strong metabolic connection to cardiovascular
disease, while type 1 diabetes (T1D, n = 173,981)[23], a type of autoimmune
diseases, was incorporated for comparison.

To explore potential mechanisms, we further tested omega-3 fatty acids against
cardiovascular related metabolic traits. We downloaded full summary statistics
from the largest available GWAS for total cholesterol (n = 1,320,016)[24], low-
density lipoprotein cholesterol (LDL-C; n = 1,320,016)[24], high-density
lipoprotein cholesterol (HDL-C; n = 1,654,960)[24], triglycerides[24,25],
apolipoprotein B (ApoB; n = 136,016)[13], apolipoprotein A (ApoA; n = 323,833)[26]
and hypertension (n = 56,637). Two triglyceride GWAS datasets were analyzed:
one based entirely outside UK Biobank (n = 1,320,016)[24], and another that
included UK Biobank samples (n = 361,194)[25]. Age, sex, principal components
and relevant study-specific covariates also have been adjusted for these
disease outcomes and metabolic traits.

150   Instrumental variable selection

We began with common SNPs (minor-allele frequency > 1 %) associated with
omega-3 levels at genome-wide significance level ($P < 5.00E-08$). Correlated
variants were then removed by linkage disequilibrium (LD) clumping (1-Mb
window, $r^2 < 0.05$) based on the 1,000 Genomes European panel. To mitigate
pleiotropic SNPs, we further applied Steiger filtering[27] discarding SNPs that
explained more variance in the outcome than in the exposure, maintaining the
correct causal direction.

158   Mendelian randomization analyses

To ensure the robustness and validity of our MR results, we employed four well-
established MR algorithms, as evaluated in previous studies[7,8]. These included:
(i) IVW Fixed-effects[28], (ii) MR-Egger[9], (iii) Weighted Mode[10], and (iv) APSS[29].
The IVW Fixed-effects model offers the greatest statistical power but assumes
that every genetic instrument is valid and that no heterogeneity exists across
instrument–outcome associations, making it sensitive to horizontal pleiotropy[8].
MR-Egger modifies this assumption by allowing a non-zero intercept, thereby
adjusting for directional pleiotropy[12]. The Weighted Mode estimator focuses on
the most common causal effect across instruments, reducing the impact of
outliers[10]. MR-APSS remains reliable even when many instruments are weak[11].
In addition, given that the *FADS* variant rs174564 accounts for a large
proportion of variance in omega-3 levels[30], we performed a single-variant Wald
Ratio analysis[31] using rs174564 or a proxy SNP in strong LD ($r^2 > 0.9$). A causal
association was accepted only when at least three of the five tests yielded
statistically significant results with consistent directional effects. The
significance threshold for *P* values was adjusted using Bonferroni correction to
account for multiple comparisons across different studies.

To ensure comparability between datasets, we standardized the SNP-effect
estimates and their standard errors. Each raw effect (β) was divided by its
standard error to create a Z-score, which we then rescaled by $\sqrt{n}$ (n = sample
size) to produce a unit-free effect ($Z/\sqrt{n}$). The corresponding standard error
was set to $1/\sqrt{n}$. This transformation eliminates differences in measurement
units and variance across studies, ensuring that subsequent instrumental-
variable analyses are conducted on a consistent scale.

SNP-exposure and SNP-outcome datasets were harmonized using the
TwoSampleMR package (version 0.5.11)[32]. IVW Fixed-effects model, MR-
Egger, Weighted Mode, and Wald Ratio analyses were also conducted using
this package. APSS was implemented with the MRAPSS package (0.0.0.9),
which restricted the analysis to SNPs in the HapMap 3 reference panel. The
background parameters were estimated by LD score regression[33], with the LD
score calculated from the 1,000 Genomes European panel.

Multivariable mendelian randomization analysis

Multivariable mendelian randomization (MVMR) analysis was performed using the TwoSampleMR package (version 0.5.11) to estimate the direct association of omega-3 fatty acids with CAD. The models were sequentially adjusted for LDL-C, triglycerides and then for both together. IVs for omega-3 fatty acids, LDL-C, and triglycerides were selected independently based on predefined criteria, followed by the removal of duplicate variants. LD clumping (1-Mb window, $r^2 < 0.05$) was subsequently conducted to ensure instrument independence. Effect alleles were harmonized across both exposures and the outcome datasets.

Mediation analysis

Mediation analysis[34] was applied to partition the total effect of genetically predicted omega-3 on the CAD into a direct effect and an indirect effect mediated through LDL-C. The total effect was estimated using the four well established MR algorithms (IVW Fixed-effects, MR-Egger, Weighted Mode, and APSS), respectively (omega-3 -> CAD). Indirect effects were assessed using a two-step MR framework (**Figure 4b**): (1) estimating the effect of omega-3 on LDL-C (β_{step1}) across MR methods, and (2) estimating the effect of LDL-C on CAD (β_{step2}) across MR methods. The indirect effect was then calculated using the product method as $\beta_{step1} \times \beta_{step2}$[35,36].

To estimate the standard error (SE) of the indirect effect, we applied two approaches: (1) the Delta method approximates the variance using the delta rule, yielding a closed-form solution ($SE_{indirect} = \text{sqrt}(\beta_{step1}^2 * SE_{step2}^2 + \beta_{step2}^2 * SE_{step1}^2)$)[37] but potentially underestimating variability when coefficient distributions are skewed; (2) the Monte Carlo (MC) method generated empirical confidence intervals by repeatedly sampling[38], offering greater robustness at the expense of higher computational cost. Both methods were implemented to ensure robustness of our inference.

Protein quantitative trait loci data analysis

To identify plasma proteins associated with circulating omega-3 levels, we
applied summary-data-based mendelian randomization (SMR)[39,40]. This
method tests whether genetic variants associated with omega-3 levels also
influence protein levels, pinpointing key circulating proteins related to omega-3
metabolism. To distinguish true associations from those arising due to LD, we
integrated the heterogeneity in dependent instruments (HEIDI) test[40]. These
analyses were conducted using the SMR portal[39], leveraging protein
quantitative trait loci (pQTL) summary statistics obtained from the Fenland
study (n = 10,708)[41]. Associations were considered statistically significant if
they met the following criteria: (i) the lead SNP in omega-3 GWAS passed the
genome-wide significant threshold (P < 5.00E-08); (ii) the SMR test passed a
Bonferroni-corrected threshold (P_{SMR} < 2.59E-05; 0.05/1,927); and (iii) there
was no evidence of horizontal pleiotropy due to LD (P_{HEIDI} > 0.01). Proteins
were considered associated with omega-3 only if significant associations were
confirmed in the two omega-3 GWAS. Gene set enrichment analysis was
conducted using ToppGene Suite[42]. Regional plots were generated by R
package locuscomparer (Version 1.0.0)[43].

236 Results

237 Genetically elevated omega-3 levels increase the risk of
238 cardiovascular outcomes

Summary statistics from a GWAS of omega-3 measure in 136,016
participants[13] were used as the primary exposure dataset. The causal effects
on seven cardiovascular-related outcomes (CAD, myocardial infarction, heart
failure, atrial fibrillation, stroke, ischemic stroke, and T2D) were examined using
five complementary MR estimates (see **Methods**). T1D, an autoimmune
disease with aetiology distinct from cardiovascular disease, was included for
comparison. A causal association was considered robust when at least three
methods showed consistent effect directions and met the Bonferroni-corrected
significance threshold (P < 0.00625; 0.05/8).

Our analysis showed that genetically elevated omega-3 levels have a
significant causal effect on the risk of CAD (P_{median} = 2.65E-04), with consistent

effect directions across all MR estimates (**Figure 2a**). These results were consistent when using the CAD GWAS exclusively from the UK Biobank (P_{median} = 2.87E-07). Similar causal relationships were observed for myocardial infarction (P_{median} = 1.03E-07) and heart failure (P_{median} = 4.84E-03). We also observed modest effects of omega-3 on the risk of atrial fibrillation (P_{median} =0.041), stroke (P_{median} = 0.038) and its ischemic subtype (P_{median} = 0.035). Although these associations did not meet the Bonferroni-corrected significance threshold, the directions of causal effects were consistent across all five MR estimates. In comparison, no causal effects were observed for T2D (P_{median} = 0.139) and T1D (P_{median} = 0.297).

We repeated the analysis using the secondary omega-3 GWAS from UK Biobank. The results confirmed the causal association of increased omega-3 levels with higher risks of CAD (P_{median} = 2.94E-03 and 5.45E-05 for respective datasets), myocardial infarction (P_{median} = 1.27E-03) and heart failure (P_{median} = 4.60E-03). All five MR estimates pointed in the same direction (**Figure S1a**). The positive association with atrial fibrillation (P_{median} = 0.065), stroke (P_{median} = 0.140), and ischemic stroke (P_{median} = 0.044) still exists, whereas no associations were detected for T2D (P_{median} = 0.126) and T1D (P_{median} = 0.727). To further validate these results, we repeated the analyses using a GWAS of DHA as the exposure. The results were highly consistent, demonstrating a significant causal effect of elevated DHA levels on the risks of CAD, myocardial infarction, and heart failure (**Figure S2**).

We next conducted sensitivity analyses by excluding genetic variants in the *FADS* gene cluster (hg19; chr11:61,067,097–62,134,826), as the fatty acid desaturases encoded in this region directly involve omega-3 metabolism[44]. The causal association with CAD (P_{median} = 9.47E-08 and 8.39E-07 for respective datasets), myocardial infarction (P_{median} = 5.70E-06) and heart failure (P_{median} = 0.016) remained significant and directionally consistent (**Figure 3a**). However, the effects on atrial fibrillation, stroke and ischemic stroke were attenuated, and the null results for T2D and T1D remained unchanged. These findings were consistent in the secondary omega-3 GWAS (**Figure 3b**).

To investigate potential reverse causation, we also performed bidirectional MR

analyses. Using genetic variants associated with these cardiovascular

outcomes as IVs, their causal effects on omega-3 levels were evaluated. We

found no evidence of the reverse causal associations (**Figure S3**), supporting

a unidirectional relationship with omega-3 levels influencing cardiovascular

outcomes. Taken together, our results suggest that elevated omega-3 levels

may increase cardiovascular risk, particularly CAD, myocardial infarction, and

heart failure.

289   Omega-3 elevates LDL-C while lowering triglycerides

To further explore the above findings, we examined the causal influence of

omega-3 fatty acids on related metabolic traits: total cholesterol, LDL-C, HDL-

C, triglycerides, ApoB, ApoA, and hypertension. Similarly, a causal association

was considered robust if at least three methods showed consistent directions

and met the Bonferroni-corrected significance threshold ($P < 0.0071$; 0.05/7).

Our analyses indicated that genetically elevated omega-3 levels significantly

increased total cholesterol (P_{median} = 7.40E-33), especially LDL-C (P_{median} =

2.50E-33). These results were highly consistent across all MR methods (**Figure**

2b). In contrast, no significant effect was observed for HDL-C (P_{median} = 0.079)

and hypertension (P_{median} = 0.215). This pattern extended to key

apolipoproteins, with a significant effect found on ApoB (P_{median} = 5.60E-08),

the key component of LDL particles, while no association was found for ApoA

(P_{median} = 0.276), the key component of HDL particles. The causal effects on

LDL-C and ApoB were also replicated using another independent omega-3

GWAS from UK Biobank (**Figure S1b**). Sensitivity analyses were also

performed by excluding genetic variants within the *FADS* gene cluster. Strong

positive causal associations of omega-3 with LDL-C and ApoB levels were still

observed (**Figure S4**).

To address potential influence of horizontal pleiotropy between omega-3 and

LDL-C mentioned in previous studies[45], we adopted more stringent criteria for

selecting IVs. Only genetic variants associated with omega-3 levels ($P < 5.00E$-

08) but not associated with LDL-C levels ($P > 0.05$), were included in the MR

analyses. Despite the reduced statistical power, a positive causal association
between omega-3 and LDL-C remained evident *(P < 0.019;* **Figure S5**).

In addition to LDL-C, our analyses demonstrated that genetically elevated
omega-3 levels significantly lowered triglycerides (P_{median} = 4.16E-03). This
result was also confirmed by another triglyceride GWAS data[25] (P_{median} = 6.80E-
04; **Figure 2b**). A consistent direction of effect on triglyceride lowering was also
observed when utilizing the omega-3 GWAS derived from UK Biobank as the
exposure (**Figure S1b**). These findings align with the American Heart
Association (AHA)'s recommendation of omega-3 for reducing triglycerides[46]

However, exclusion of genetic variants within the *FADS* gene cluster reversed
this association in a positive direction. This result was further validated using
the secondary omega-3 GWAS data (**Figure S4**), highlighting the complex role
of omega-3 in triglyceride reduction. Specifically, the triglyceride-lowering effect
appears to be primarily mediated through fatty acid desaturase activity, while
omega-3-associated variants outside the *FADS* cluster were linked to
increased triglyceride levels. These findings suggest that the effectiveness of
omega-3 supplementation in reducing triglycerides may depend on an
individual's fatty acid desaturase activity.

To validate the MR results indicating that omega-3 elevates LDL-C while
lowering triglycerides, we revisited data from previous clinical trials. To
minimize the influence of cholesterol-lowering drugs, we first analyzed data
from the Comparing EPA to DHA trial (ComparED; NCT01810003)[47], which
assessed changes in blood lipids following EPA or DHA intake among adults
without a history of cardiovascular disease[47]. Compared to corn oil, both EPA
and DHA significantly increased LDL-C levels while reducing triglycerides. This
effect was markedly stronger with DHA, demonstrating a mean LDL-C increase
of 0.16 mmol/L (*P* < 0.0001) and a mean triglyceride reduction of 0.25 mmol/L
(*P* < 0.0001) over a 10-week follow-up[47].

Next, we revisited data from the STRENGTH trial[4]. Although all participants
were on statin therapy, those in the omega-3 CA group showed a significant
increase in LDL-C compared with the corn oil group (geometric mean ratio =

1.03; P < 0.001) and a substantial reduction in triglyceride levels (geometric

mean ratio = 0.82; P < 0.001)[4].

We also investigated data from the REDUCE-IT trial[3]. Due to the use of mineral

oil as the control, between-group comparisons were not considered. As all

participants were receiving statin therapy, we expected a mean LDL-C

reduction of approximately 25%[48]. However, within the icosapent ethyl group,

LDL-C levels significantly increased by 3.1 % from the baseline (P < 0.001). In

contrast, triglycerides decreased by 18.3 % (P < 0.001) following 12 months of

treatment.

Collectively, findings from previous clinical trials also supported our MR results

that omega-3 supplementation can elevate LDL-C levels while lowering

triglycerides.

355 The protective effect of omega-3 on CAD depends on lipid
356 control

The above analyses suggest that with appropriate LDL-C control, omega-3 fatty

acids may provide net cardiovascular protection. To test this hypothesis, we

estimated the effect of omega-3 on cardiovascular outcome by controlling LDL-

C-associated variants using MVMR algorithm (see **Methods**). To maximize

statistical power, CAD was selected as the outcome due to its largest sample

size and the availability of additional CAD dataset for replication. Our results

showed that, after adjusting for LDL-C's genetic contribution, the effect of

omega-3 on CAD became protective. The association remained consistent

when replicated using the secondary omega-3 GWAS or an alternative CAD

GWAS, yielding a combined effect estimate of approximately -0.025 ($P_{combined}$

= 0.0225) (**Figure 4a** and **Table S2**). In contrast, adjusting for the genetic

variants associated with triglycerides didn't change the direction of the

associations (**Figure 4a** and **Table S3**). However, we found that adjusting for

the genetic effects of both LDL-C and triglycerides further strengthened omega-

3's protective association with CAD ($\beta_{combined}$ = -0.066, $P_{combined}$ = 1.28E-11;

Figure 4a and **Table S4**). These findings highlight the critical role of lipid control,

particularly LDL-C, in optimizing the cardioprotective effects of omega-3.

To further evaluate the role of LDL-C in mediating the effect of omega-3 fatty
acids on CAD risk, we decomposed the total effect into direct and indirect
components using mediation analysis (see **Methods**). The indirect effect on
CAD through LDL-C was significant (β_{median} = 0.031; P_{median} = 2.40E-12; **Figure
4b**), explaining approximately 38.0–81.9% of the total effect of omega-3 on
CAD risk across four MR estimates (**Figure 4b** and **Table S5**). These results
remained robust when replicated using an alternative CAD GWAS (**Figure S6**
and **Table S5**). These findings suggest LDL-C as a major mediator of the
association between elevated omega-3 and CAD risk and highlight the potential
importance of targeting LDL-C reduction in this pathway.

To validate the significance of LDL-C management in optimizing omega-3
benefits, we revisited data from the STRENGTH and REDUCE-IT trials, both of
which evaluated the effect of high-dose omega-3 on cardiovascular events[3,4].
Subgroup analyses partially support our findings (**Figure 4c**). In STRENGTH,
compared to corn oil, omega-3 CA appeared more effective in participants
receiving high-intensity statin therapy (Hazard Ratio [HR] = 0.94) than in other
participants (HR = 1.04), though this difference did not reach statistical
significance (P = 0.28). Notably, in participants receiving combined statin and
ezetimibe therapy, a regimen that achieves greater LDL-C reduction, omega-3
CA significantly lowered cardiovascular risk compared to corn oil (HR = 0.54,
95% Confidence Interval [CI]: 0.34-0.86; P = 0.0094)[49].

A similar trend was observed in the REDUCE-IT trial, where icosapent ethyl
conferred a significant cardiovascular benefit over mineral oil among
participants receiving high-intensity statin therapy (HR = 0.69, 95% CI: 0.58–
0.82; P = 2.60E-05). In contrast, no benefit was seen in the low-intensity statin
group (HR = 1.12, 95% CI: 0.74–1.69; P = 0.59). The difference between the
two statin groups was significant (Cochran's Q, P = 0.034), indicating that
patients on high-intensity statin therapy gained substantially more from
icosapent ethyl than those on low-intensity regimens. In the smaller subgroup
receiving both a statin and ezetimibe, icosapent ethyl also suggested a
protective effect (HR = 0.82; 95% CI, 0.57–1.16), although this was not
significantly different from the statin-only group. This may be due to the limited

sample size and the fact that 93% of participants were already on at least moderate-intensity statin therapy[3].

Together with evidence from clinical trials, our findings suggest the importance of lowering LDL to optimize the cardioprotective effects of omega-3. However, the potential for enhanced benefits through concurrent management of triglycerides and LDL-C requires further validation.

Plasma proteins associated with omega-3 levels

Circulating proteins are often used as biomarkers or targets for pharmacological intervention[41]. We incorporated pQTL data from the Fenland study (n = 10,708) to detect plasma proteins associated with omega-3 levels. Using SMR analysis combined with the HEIDI test (see **Methods**), we identified 9 candidate proteins that passed the Bonferroni-corrected threshold (P_{SMR} < 2.59E-05; 0.05/1,927). Of these, five were further replicated in the secondary omega-3 GWAS data (**Figure 5**), including Glucokinase Regulator (GCKR), Angiopoietin Like 3 (ANGPTL3), Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), T Cell Immunoglobulin And Mucin Domain Containing 4 (TIMD4), and ApoB (**Table S6**). Regional plots revealed that genetic variants linked to the expression of these proteins well colocalized with signals for omega-3 levels (**Figure S7 - S8**), highlighting strong associations between these circulating proteins and omega-3 metabolism.

Gene set enrichment analysis demonstrated that these proteins were highly enriched in pathways related to lipid homeostasis (GO:0055088; FDR = 1.91E-04) and triglyceride metabolic process (GO:0006641; FDR = 2.04E-04). Of these, ANGPTL3 (β_{SMR} = 0.197, P_{SMR} = 1.22E-27 and P_{HEIDI} = 0.898), PCSK9 (β_{SMR} = 0.192, P_{smr} = 1.15E-21 and P_{HEIDI} = 0.119), and ApoB (β_{SMR} = 0.488, P_{smr} = 1.57E-10 and P_{HEIDI} = 0.153) demonstrated a positive correlation with omega-3 levels. Their upregulations have been found linked to increased LDL-C levels and a higher risk of cardiovascular events[50-52]. These genetic findings suggest a potential mechanism whereby higher omega-3 levels are positively associated with proteins known to increase LDL-C (PCSK9, ANGPTL3, ApoB), which could partly explain their potential link to increased cardiovascular risk.

However, this hypothesis requires further mechanistic studies and clinical
validation.

Notably, PCSK9 and ANGPTL3 are established targets for FDA-approved
drugs. Evolocumab, a PCSK9 inhibitor, has been shown to reduce LDL-C levels
by 59% compared to placebo at 48 weeks[53], while Evinacumab, an ANGPTL3
inhibitor, achieves a 49% reduction in LDL-C and approximately 50%
reductions in triglyceride levels relative to placebo at 24 weeks in patients with
familial hypercholesterolemia[54]. In light of the MVMR findings, omega-3
supplementation could be a valuable complement to PCSK9-targeted and
ANGPTL3-targeted therapies. These hypotheses warrant further investigation
to determine whether such combinations could reduce omega-3's adverse
effects on LDL-C and enable its cardiovascular benefits.

449 Discussion

Omega-3 fatty acids have long been promoted for cardiovascular health[55,56].
However, our findings suggest that the cardiovascular benefits of omega-3 fatty
acids could be context-dependent.

We showed that genetically elevated omega-3 levels were associated with
increased cardiovascular risk, particularly CAD, myocardial infarction, and
heart failure. These results were consistent across independent omega-3 and
DHA GWAS datasets. Additional sensitivity analyses supported the positive
causal relationship between higher omega-3 levels and increased
cardiovascular risk. Previous studies have also reported an association
between omega-3 intake and a higher risk of atrial fibrillation[57]. Collectively,
these findings suggest that using omega-3 supplementation alone for
cardiovascular protection should be considered with caution.

Further analysis of metabolic traits revealed that elevated omega-3 levels were
significantly linked to increased LDL-C, ApoB, and total cholesterol levels.
Circulating proteins known to increase LDL-C, such as PCSK9, ANGPTL3,
ApoB, were also found positively associated with omega-3 levels. These
findings may partially explain the positive association observed between

omega-3 and cardiovascular risk. However, mechanistic studies and clinical

investigations are needed to confirm these findings and clarify the underlying

pathways.

Omega-3 also showed a triglyceride-lowering effect, though this benefit

appeared to be mainly driven by the *FADS* gene cluster. These results align

with the AHA's recommendation for omega-3 use in lowering triglycerides[46].

Previous clinical trials, including ComparED, STRENGTH and REDUCE-IT,

consistently demonstrated that omega-3 supplementation could increase LDL-

C while reducing triglycerides, supporting the patterns observed in our MR

analyses.

Notably, after adjusting for variants associated with LDL-C, we found a

protective effect of omega-3 on CAD. The protective effect was further

strengthened by controlling both LDL-C and triglycerides. Mediation analysis

showed that about half of the effect of omega-3 on CAD risk was explained by

LDL-C, suggesting the importance of LCL-C management in optimizing the

cardiovascular benefits of omega-3. Data from the STRENGTH[4] and REDUCE-

IT[3] trials also support this. In both studies, the protective effect of omega-3

appeared to be associated with the intensity of LDL-C lowering therapy.

Together, these findings suggest the need for optimal lipid management,

particularly LDL-C, when using omega-3 supplementation to achieve

cardiovascular protection.

A recent study showed that regular use of fish oil supplements may increase

the risk of first-time heart disease and stroke in individuals without prior

cardiovascular conditions, while it may help slow disease progression in those

with existing cardiovascular disease[58]. Our findings provide a potential

explanation for the seemingly contradictory observations: Individuals without

prior cardiovascular disease often use omega-3 supplementation without

effective LDL control, which may result in increased cardiovascular risk.

However, this hypothesis needs to be further investigated.

Studies have shown that omega-3 fatty acids have the anti-

inflammatoryproperties[59]. Animal study showed that omega-3 binds to GPR120

in macrophages to inhibit both TLR and TNF-α signalling pathways, mediating

the anti-inflammatory effects[60]. Additionally, studies using LDL receptor-

knockout mice have demonstrated that the anti-inflammatory effect of omega-

3 is independent of lipid metabolism[61]. These findings suggest that the

cardiovascular benefits of omega-3 may be enhanced by its anti-inflammatory

actions, particularly when the adverse effects on LDL-C are effectively

managed.

Additionally, PCSK9 and ANGPTL3 are established targets of approved lipid-

lowering drugs[62,63]. Their positive associations with omega-3 levels raise the

possibility that omega-3 supplementation may interact with these pathways.

Further clinical studies are needed to assess whether combining omega-3 with

therapies targeting PCSK9 or ANGPTL3 could enhance cardiovascular benefits.

We acknowledge that MR methods rely on strong assumptions[11,64]. The

selection of valid IVs is crucial for producing reliable results. We restricted the

analyses to GWAS with large sample size (n > 50,000) and applied Steiger

filtering to exclude potential pleiotropy. Multiple well-established MR methods

were also utilized in combination to further enhance the reliability of the findings.

Despite these, completely ruling out horizontal pleiotropy and ensuring

sufficient statistical power remain challenging. In addition, some MR analyses

were conducted based on a one-sample test, where both exposure and

outcomes were collected from the same source, such as the UK Biobank.

Although this test minimizes differences in population ancestry and composition,

it is more susceptible to overfitting and weak instrument bias[65]. Furthermore,

we also noted that confounding factors for the subgroup analyses from

STRENGTH and REDUCE-IT trials could not be fully controlled without access

to raw data.

In summary, this study suggests that the cardiovascular benefits of omega-3

fatty acids are context-dependent, particularly influenced by LDL-C control. We

hypothesize that combining omega-3 supplementation with effective lipid-

lowering therapy may help maximize cardiovascular benefit, a concept that

warrants further clinical investigation.

Conclusion

Our results suggest that the cardiovascular benefits of omega-3 fatty acids are context-dependent, showing protective effects when lipids, particularly LDL-C, are well controlled. We hypothesize that combining omega-3 supplementation with effective lipid-lowering therapy may help maximize cardiovascular benefit, a concept that warrants further clinical investigation.

Acknowledgments

We gratefully acknowledge funding supports from the Shenzhen-Hong Kong Jointly Funded Project (Category A; SGDX20230116093201002) and the Stability Support for Higher Education from Shenzhen Science and Technology Program, the Guangdong Natural Science Foundation Youth Enhancement Project (2024A1515030287), 1+1+1 CUHK-CUHK(SZ)-GDSTC Joint Collaboration Fund (GRDP2025-056 and YSP05) and the National Natural Science Foundation of China (82471825). We also extend our thanks to the faculty development grant (Project number: H800005) from the Hang Seng University of Hong Kong and the Warshel Institute for Computational Biology and their funding support from Shenzhen City and Longgang District (LGKCSDPT2024001). The authors thank the anonymous reviewers for their constructive comments and valuable suggestions that helped to improve the quality of the manuscript.

Author contributions

Y.-F. Wang conceived the study. J.-H. Yu and C.-J. Li took the lead in data analysis. J.-H. Yu, C.-J. Z. Liu, Li, Y.-D. Chen, Y. Lei, D.-Y. Li, W. Ma, Y. Wang, Y. Yang, and R. Wang collected GWAS summary data. J.-H. Yu, C.-J. Li, Y. Wang, Y. Yang, R. Wang, and Y.-F. Wang contributed to the interpretation of the findings. J.-H. Yu, C.-J. Li and Y.-F. Wang wrote the manuscript. All authors read and contributed to the manuscript.

Competing interests

557   The authors declare no competing interests.

Role of study sponsors

559   The funders had no role in the design and conduct of the study; collection,
560   management, analysis, and interpretation of the data; preparation, review, or
561   approval of the manuscript; and decision to submit the manuscript for
562   publication.

Data availability

564   See **Table S1**.

Declaration of generative AI

566   We cautiously used ChatGPT 4.1 for linguistic and grammatical refinement to

567   improve the readability during the proofreading. After using this tool, the authors

568   reviewed and edited the content as needed and took full responsibility for the

569   content of the publication.

References

1.   Jayedi A, Shab-Bidar S. Fish Consumption and the Risk of Chronic Disease: An Umbrella Review of Meta-Analyses of Prospective Cohort Studies. *Adv Nutr*. Sep 1 2020;11(5):1123-1133. doi:10.1093/advances/nmaa029

2.   Del Gobbo LC, Imamura F, Aslibekyan S, et al. omega-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. *JAMA Intern Med*. Aug 1 2016;176(8):1155-66. doi:10.1001/jamainternmed.2016.2925

3.   Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *The New England journal of medicine*. Jan 3 2019;380(1):11-22. doi:10.1056/NEJMoa1812792

4.   Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. *JAMA*. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258

5.   Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. *Cold Spring Harb Perspect Med*. Jan 4 2022;12(1)doi:10.1101/cshperspect.a040501

6.   Bowden J, M FDG, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I^2 statistic. *International Journal of Epidemiology*. 2016/12;45(6)doi:10.1093/ije/dyw220

7.   Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in genome-wide association studies: A review. *Comput Struct Biotechnol J*. 2022;20:2338-2351. doi:10.1016/j.csbj.2022.05.015

8.   Hu X, Cai M, Xiao J, et al. Benchmarking Mendelian randomization methods for causal inference using genome-wide association study summary statistics. *Am J Hum Genet*. Aug 8 2024;111(8):1717-1735. doi:10.1016/j.ajhg.2024.06.016

9.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080

10.   Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*. Dec 1 2017;46(6):1985-1998. doi:10.1093/ije/dyx102

11.   Hu X, Zhao J, Lin Z, et al. Mendelian randomization for causal inference accounting for pleiotropy and sample structure using genome-wide summary statistics. *Proc Natl Acad Sci U S A*. Jul 12 2022;119(28):e2106858119. doi:10.1073/pnas.2106858119

12.   Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. *Genetic epidemiology*. Jun 2020;44(4):313-329. doi:10.1002/gepi.22295

13.   Karjalainen MK, Karthikeyan S, Oliver-Williams C, et al. Genome-wide characterization of circulating metabolic biomarkers. *Nature*. Apr 2024;628(8006):130-138. doi:10.1038/s41586-024-07148-y

14.   Richardson TG, Leyden GM, Wang Q, et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. *PLoS Biol*. Feb 2022;20(2):e3001547. doi:10.1371/journal.pbio.3001547

15.   Cerezo M, Sollis E, Ji Y, et al. The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity. *Nucleic Acids Res*. Jan 6 2025;53(D1):D998-D1005. doi:10.1093/nar/gkae1070

16.   van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res*. Feb 2 2018;122(3):433-443. doi:10.1161/CIRCRESAHA.117.312086

17.   Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nature genetics*. Dec 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6

18.   Hartiala JA, Han Y, Jia Q, et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. *Eur Heart J*. Mar 1 2021;42(9):919-933. doi:10.1093/eurheartj/ehaa1040

19. Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun*. Jan 9 2020;11(1):163. doi:10.1038/s41467-019-13690-5

20. Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat Genet*. Jun 11 2018;50(9):1225-1233. doi:10.1038/s41588-018-0133-9

21. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. Apr 2018;50(4):524-537. doi:10.1038/s41588-018-0058-3

22. Xue A, Wu Y, Zhu Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun*. Jul 27 2018;9(1):2941. doi:10.1038/s41467-018-04951-w

23. Crouch DJM, Inshaw JRJ, Robertson CC, et al. Bayesian Effect Size Ranking to Prioritise Genetic Risk Variants in Common Diseases for Follow-Up Studies. *Genet Epidemiol*. Jan 2025;49(1):e22608. doi:10.1002/gepi.22608

24. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature*. Dec 2021;600(7890):675-679. doi:10.1038/s41586-021-04064-3

25. Koskeridis F, Evangelou E, Said S, et al. Pleiotropic genetic architecture and novel loci for C-reactive protein levels. *Nat Commun*. Nov 14 2022;13(1):6939. doi:10.1038/s41467-022-34688-6

26. Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nature genetics*. Feb 2021;53(2):185-194. doi:10.1038/s41588-020-00757-z

27. Hemani G, Tilling K, Smith GD. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genetics*. 2017;13(11)doi:10.1371/journal.pgen.1007081

28. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. Nov 2013;37(7):658-65. doi:10.1002/gepi.21758

29. Cinelli C, LaPierre N, Hill BL, Sankararaman S, Eskin E. Robust Mendelian randomization in the presence of residual population stratification, batch effects and horizontal pleiotropy. *Nat Commun*. Mar 1 2022;13(1):1093. doi:10.1038/s41467-022-28553-9

30. Guan W, Steffen BT, Lemaitre RN, et al. Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium. *Circ Cardiovasc Genet*. Jun 2014;7(3):321-331. doi:10.1161/CIRCGENETICS.113.000208

31. Wald A. The Fitting of Straight Lines if Both Variables are Subject to Error. *The Annals of Mathematical Statistics*. 1940;11(3):284-300, 17.

32. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. May 30 2018;7doi:10.7554/eLife.34408

33. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature genetics*. Mar 2015;47(3):291-5. doi:10.1038/ng.3211

34. Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol*. May 2021;36(5):465-478. doi:10.1007/s10654-021-00757-1

35. Cheng C, Spiegelman D, Li F. Estimating the natural indirect effect and the mediation proportion via the product method. *BMC Med Res Methodol*. Nov 20 2021;21(1):253. doi:10.1186/s12874-021-01425-4

36. Cheng C, Spiegelman D, Li F. Is the Product Method More Efficient Than the Difference Method for Assessing Mediation? *Am J Epidemiol*. Jan 6 2023;192(1):84-92. doi:10.1093/aje/kwac144

37. Sobel ME. Asymptotic Confidence Intervals for Indirect Effects in Structural Equation Models. *Sociological Methodology* 1982;

38. David P. MacKinnon CML, Jeanne M. Hoffman, Stephen G. West, and Virgil, Sheets. A Comparison of Methods to Test Mediation and Other Intervening Variable Effects. *Psychol Methods*. 2002;

39.   Guo Y, Xu T, Luo J, et al. SMR-Portal: an online platform for integrative analysis of GWAS and xQTL data to identify complex trait genes. *Nat Methods*. Feb 2025;22(2):220-222. doi:10.1038/s41592-024-02561-7

40.   Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet*. May 2016;48(5):481-7. doi:10.1038/ng.3538

41.   Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic convergence of human diseases. *Science*. Nov 12 2021;374(6569):eabj1541. doi:10.1126/science.abj1541

42.   Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic acids research*. Jul 2009;37(Web Server issue):W305-11. doi:10.1093/nar/gkp427

43.   Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with gene expression complicate GWAS follow-up. *Nat Genet*. May 2019;51(5):768-769. doi:10.1038/s41588-019-0404-0

44.   Loukil I, Mutch DM, Plourde M. Genetic association between FADS and ELOVL polymorphisms and the circulating levels of EPA/DHA in humans: a scoping review. *Genes Nutr*. Jun 6 2024;19(1):11. doi:10.1186/s12263-024-00747-4

45.   Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. *BMC Med*. Jun 13 2022;20(1):210. doi:10.1186/s12916-022-02399-w

46.   Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. Nov 19 2002;106(21):2747-57. doi:10.1161/01.cir.0000038493.65177.94

47.   Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (CompareD) Study. *Am J Clin Nutr*. Aug 2016;104(2):280-7. doi:10.3945/ajcn.116.131896

48.   Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol*. May 1995;15(5):678-82. doi:10.1161/01.atv.15.5.678

49.   Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. Jun 18 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489

50.   Huijgen R, Sjouke B, Vis K, et al. Genetic variation inAPOB,PCSK9, andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels. *Human Mutation*. 2012;33(2):448-455. doi:10.1002/humu.21660

51.   Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. *Trends in Cardiovascular Medicine*. 2024;34(4):215-222. doi:10.1016/j.tcm.2023.01.008

52.   Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. *New England Journal of Medicine*. 2017;377(3):211-221. doi:10.1056/NEJMoa1612790

53.   Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine*. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

54.   Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *New England Journal of Medicine*. 2020;383(8):711-720. doi:10.1056/NEJMoa2004215

55.   Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol*. Nov 8 2011;58(20):2047-67. doi:10.1016/j.jacc.2011.06.063

56.   Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr*. Jul 2006;84(1):5-17. doi:10.1093/ajcn/84.1.5

57.   Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized

Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *Circulation*. Dec 21 2021;144(25):1981-1990. doi:10.1161/CIRCULATIONAHA.121.055654

58.   Chen G, Qian ZM, Zhang J, et al. Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study. *BMJ Med*. 2024;3(1):e000451. doi:10.1136/bmjmed-2022-000451

59.   Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. *Circulation*. Jul 15 2003;108(2):155-60. doi:10.1161/01.CIR.0000079224.46084.C2

60.   Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. Sep 3 2010;142(5):687-98. doi:10.1016/j.cell.2010.07.041

61.   Brown AL, Zhu X, Rong S, et al. Omega-3 fatty acids ameliorate atherosclerosis by favorably altering monocyte subsets and limiting monocyte recruitment to aortic lesions. *Arterioscler Thromb Vasc Biol*. Sep 2012;32(9):2122-30. doi:10.1161/ATVBAHA.112.253435

62.   Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *N Engl J Med*. Aug 20 2020;383(8):711-720. doi:10.1056/NEJMoa2004215

63.   Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. May 4 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

64.   Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I^2 statistic. *Int J Epidemiol*. Dec 1 2016;45(6):1961-1974. doi:10.1093/ije/dyw220

65.   Nguyen K, Mitchell BD. A Guide to Understanding Mendelian Randomization Studies. *Arthritis Care Res (Hoboken)*. Nov 2024;76(11):1451-1460. doi:10.1002/acr.25400

Figure legends

Figure 1 Flowchart of Study Design.

Figure 2 Effect of omega-3 on cardiovascular events (a) and related metabolic traits (b) estimated across five mendelian randomization (MR) methods. nIVs, number of instrumental variables (IVs) used in the analysis. SE, standard error of the effect estimate. The APSS algorithm employs considerably fewer instrumental variables because it restricts analysis to SNPs included in the HapMap 3 reference panel (See Methods).

Figure 3 Effects of omega-3 on cardiovascular events with or without inclusion of variants in the FADS gene cluster. (a) Primary omega-3 GWAS derived from a multi-cohort study was used as the exposure. (b) Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the exposure. The *FADS* gene cluster was defined as a region in hg19; chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold was set to be 0.00625 (0.05/8).

Figure 4 Enhanced Lipid control is essential for omega-3's cardiovascular protection. a) The direct effect of omega-3 on coronary artery disease by subsequently adjusting for variants associated with LDL-C, triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total effect of genetically predicted omega-3 on CAD. Step 1 (solid line) represents the effect of omega-3 on LDL-C, and Step 2 (solid line) represents the effect of LDL-C on CAD. The dashed line indicates the indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs calculated using the Delta method (red) and Monte Carlo method (green). Yellow triangles represent proportion of the indirect effect relative to the total effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and REDUCE-IT trials showed that the protective effect of omega-3 appeared to be associated with the intensity of LDL-C lowering therapy.

Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci associated with omega-3 levels. Red dots show the results derived from the

796 primary omega-3 GWAS, and green dots represent the results based on the

797 secondary omega-3 GWAS. SE stands for Standard error.

Figure 1 Flowchart of Study Design

a)

Disease outcomes	Methods	nIVs	Beta	SE	*P*-value	Beta (Confidence Interval)
CAD (2022) (181, 522 cases, 984, 168 controls)						
	IVW	131	0.065	0.010	1.83e−11	
	MR Egger	131	0.037	0.018	4.16e−02	
	Weighted mode	131	0.019	0.005	2.65e−04	
	APSS	83	0.141	0.023	6.64e−10	
	FADS (rs174564−A)	1	0.012	0.006	3.70e−02	
CAD (2017) (34, 541cases, 261, 984 controls)						
	IVW	124	0.123	0.018	2.18e−12	
	MR Egger	124	0.074	0.033	2.45e−02	
	Weighted mode	124	0.052	0.010	2.87e−07	
	APSS	82	0.244	0.038	1.61e−10	
	FADS (rs174564−A)	1	0.036	0.012	2.00e−03	
Myocardial Infarction (61, 505 cases, 577, 716 controls)						
	IVW	121	0.068	0.009	4.88e−13	
	MR Egger	121	0.045	0.018	1.12e−02	
	Weighted mode	121	0.036	0.006	1.03e−07	
	APSS	82	0.128	0.020	7.03e−11	
	FADS (rs174564−A)	1	0.022	0.008	4.20e−03	
Heart Failure (47, 309 cases, 930, 014 controls)						
	IVW	123	0.019	0.004	1.16e−05	
	MR Egger	123	0.027	0.008	1.65e−03	
	Weighted mode	123	0.017	0.006	4.90e−03	
	APSS	82	0.024	0.009	4.84e−03	
	FADS (rs174564−A)	1	0.015	0.006	2.10e−02	
Atrial Fibrillation (60, 620 cases, 970, 216 controls)						
	IVW	131	0.008	0.003	9.45e−03	
	MR Egger	131	0.014	0.006	2.19e−02	
	Weighted mode	131	0.010	0.005	4.12e−02	
	APSS	83	0.011	0.006	7.22e−02	
	FADS (rs174564−A)	1	0.011	0.006	6.50e−02	
Stroke (40, 585 cases, 406, 111 controls)						
	IVW	121	0.018	0.006	1.40e−03	
	MR Egger	121	0.019	0.011	8.48e−02	
	Weighted mode	121	0.018	0.009	3.78e−02	
	APSS	83	0.015	0.011	1.79e−01	
	FADS (rs174564−A)	1	0.020	0.009	3.60e−02	
Ischemic Stroke (4, 217 cases, 406, 111 controls)						
	IVW	121	0.019	0.006	7.51e−04	
	MR Egger	121	0.022	0.011	4.60e−02	
	Weighted mode	121	0.018	0.009	3.52e−02	
	APSS	83	0.020	0.012	8.44e−02	
	FADS (rs174564−A)	1	0.024	0.010	1.29e−02	
Type 2 Diabetes (62, 892 cases, 596, 424 controls)						
	IVW	57	−0.010	0.012	3.97e−01	
	MR Egger	57	−0.001	0.019	9.62e−01	
	Weighted mode	57	0.025	0.008	3.71e−03	
	APSS	65	−0.022	0.015	1.39e−01	
	FADS (rs174564−A)	1	0.031	0.008	2.00e−04	
Type 1 Diabetes (n = 181, 214 samples)						
	IVW	91	−0.012	0.011	2.97e−01	
	MR Egger	91	0.003	0.020	8.67e−01	
	Weighted mode	91	0.010	0.013	4.44e−01	
	APSS	75	−0.031	0.017	6.91e−02	
	FADS (rs174564−A)	1	0.026	0.015	8.00e−02	

−0.2   0   0.3

b)

Metabolic traits	Methods	nIVs	Beta	SE	*P*-value	Beta (Confidence Interval)
Total Cholesterol (n = 1, 320, 016)						
	IVW	102	0.321	0.027	7.37e−33	
	MR Egger	102	0.226	0.047	6.70e−06	
	Weighted mode	102	0.147	0.004	3.55e−56	
	APSS	60	0.458	0.057	1.55e−15	
	FADS (rs174564−A)	1	0.163	0.005	1.85e−194	
LDL−C (n = 1, 320, 016)						
	IVW	112	0.250	0.021	2.48e−33	
	MR Egger	112	0.195	0.038	1.17e−06	
	Weighted mode	112	0.148	0.005	1.59e−57	
	APSS	68	0.330	0.044	9.00e−14	
	FADS (rs174564−A)	1	0.168	0.006	3.11e−191	
HDL−C (n = 1, 654, 960)						
	IVW	111	0.051	0.029	7.92e−02	
	MR Egger	111	0.073	0.054	1.78e−01	
	Weighted mode	111	0.157	0.005	9.01e−59	
	APSS	67	−0.087	0.056	1.22e−01	
	FADS (rs174564−A)	1	0.170	0.005	2.99e−243	
Triglycerides (2021) (n = 1,320,016)						
	IVW	112	0.007	0.032	8.30e−01	
	MR Egger	112	−0.169	0.058	4.16e−03	
	Weighted mode	112	−0.182	0.006	8.69e−59	
	APSS	65	0.079	0.048	9.88e−02	
	FADS (rs174564−A)	1	−0.205	0.006	2.42e−288	
Triglycerides (2022) (n = 361,194)						
	IVW	94	0.001	0.033	9.69e−01	
	MR Egger	94	−0.196	0.056	6.80e−04	
	Weighted mode	94	−0.176	0.009	3.61e−33	
	APSS	69	0.009	0.052	8.64e−01	
	FADS (rs174564−A)	1	−0.203	0.010	1.03e−83	
ApoB (n = 136, 016)						
	IVW	90	0.271	0.032	2.09e−17	
	MR Egger	90	0.109	0.053	4.40e−02	
	Weighted mode	90	0.091	0.013	2.61e−10	
	APSS	51	0.284	0.060	2.01e−06	
	FADS (rs174564−A)	1	0.093	0.017	5.61e−08	
ApoA (n = 323, 833)						
	IVW	23	0.074	0.068	2.76e−01	
	MR Egger	23	−0.03	0.166	8.58e−01	
	Weighted mode	23	0.018	0.037	6.36e−01	
	APSS	50	−0.101	0.066	1.27e−01	
	FADS (rs174550−T)	1	0.169	0.011	1.23e−52	
Hypertension (28, 391 cases, 28, 246 controls)						
	IVW	121	0.008	0.014	5.53e−01	
	MR Egger	121	−0.033	0.026	2.03e−01	
	Weighted mode	121	−0.028	0.023	2.15e−01	
	APSS	81	0.033	0.024	1.61e−01	
	FADS (rs174564−A)	1	−0.028	0.026	2.88e−01	

Figure 2 Effect of omega-3 on cardiovascular events (a) and related metabolic traits (b) estimated across five mendelian randomization (MR) methods. nIVs, number of instrumental variables (IVs) used in the analysis. SE, standard error of the effect estimate. The APSS algorithm employs considerably fewer instrumental variables because it restricts analysis to SNPs included in the HapMap 3 reference panel (See Methods).

Figure 3 Effects of omega-3 on cardiovascular events with or without inclusion of variants in the *FADS* gene cluster. (a) Primary omega-3 GWAS derived from a multi-cohort study was used as the exposure. (b) Secondary omega-3 GWAS derived from UK Biobank (2022) was used as the exposure. The *FADS* gene cluster was defined as a region in hg19: chr11:61,067,097–62,134,826. The Bonferroni-adjusted significance threshold was set to be 0.00625 (0.05/8)

a)

Exposure	Outcome	Beta	SE	*P*-Value	Beta Coefficient (95% CI)
Non-adjusted					
Primary omega-3 (2024)	CAD (2022)	0.065	0.010	1.83e-11	
Primary omega-3 (2024)	CAD (2017)	0.123	0.018	2.18e-12	
Secondary omega-3 (2022)	CAD (2022)	0.031	0.008	1.21e-04	
Secondary omega-3 (2022)	CAD (2017)	0.066	0.012	1.26e-07	
Combined		**0.055**	**0.005**	**0**	
LDL-C-adjusted					
Primary omega-3 (2024)	CAD (2022)	-0.049	0.023	3.78e-02	
Primary omega-3 (2024)	CAD (2017)	-0.018	0.025	4.67e-01	
Secondary omega-3 (2022)	CAD (2022)	-0.026	0.020	1.91e-01	
Secondary omega-3 (2022)	CAD (2017)	-0.010	0.021	6.18e-01	
Combined		**-0.025**	**0.011**	**2.25e-02**	
Triglycerides-adjusted					
Primary omega-3 (2024)	CAD (2022)	0.165	0.021	8.56e-15	
Primary omega-3 (2024)	CAD (2017)	0.179	0.022	3.98e-16	
Secondary omega-3 (2022)	CAD (2022)	0.060	0.019	1.51e-03	
Secondary omega-3 (2022)	CAD (2017)	0.081	0.021	8.63e-05	
Combined		**0.116**	**0.010**	**0**	
LDL-C and Triglycerides-adjusted					
Primary omega-3 (2024)	CAD (2022)	-0.072	0.021	4.85e-04	
Primary omega-3 (2024)	CAD (2017)	-0.052	0.022	1.68e-02	
Secondary omega-3 (2022)	CAD (2022)	-0.073	0.018	4.10e-05	
Secondary omega-3 (2022)	CAD (2017)	-0.065	0.019	5.89e-04	
Combined		**-0.066**	**0.010**	**1.28e-11**	

b)

c)

Clinical trial	Placebo	Subgroup	Hazard ratio (95% CI)
STRENGTH, 2020	Corn oil	Baseline statin intensity	
Omega-3 CA		High	0.94 (0.81−1.08)
		Other	1.04 (0.91−1.20)
		Ezetimibe use	
		Yes	0.54 (0.34−0.86)
		No	1.02 (0.92−1.13)
REDUCE−IT, 2019	Mineral oil	Baseline statin intensity	
Icosapent Ethyl		High	0.69 (0.58−0.82)
		Moderate	0.76 (0.67−0.86)
		Low	1.12 (0.74−1.69)
		Ezetimibe use	
		Yes	0.82 (0.57−1.16)
		No	0.75 (0.67−0.83)

P = 0.0094 (STRENGTH Ezetimibe use)
P = 0.034 (REDUCE-IT Baseline statin intensity)

Figure 4 Enhanced Lipid control is essential for omega-3's cardiovascular protection. a) The direct effect of omega-3 on coronary artery disease by subsequently adjusting for variants associated with LDL-C, triglycerides and both lipid traits. b) Mediation analysis of the effect of omega-3 fatty acids on CAD risk through LDL-C. Red solid line illustrates the total effect of genetically predicted omega-3 on CAD. Step 1 (solid line) represents the effect of omega-3 on LDL-C, and Step 2 (solid line) represents the effect of LDL-C on CAD. The dashed line indicates the indirect effect mediated by LDL-C. Indirect effect estimates of omega-3 on CAD through LDL-C using 4 MR methods. Error bars represent 95% CIs calculated using the Delta method (red) and Monte Carlo method (green). Yellow triangles represent proportion of the indirect effect relative to the total effect across 4 MR methods. c) Subgroup analyses from the STRENGTH and REDUCE-IT trials showed that the protective effect of omega-3 appeared to be associated with the intensity of LDL-C lowering therapy.

Colocalization	β_{SMR}	SE_{SMR}	P_{SMR}	P_{HEIDI}	β_{SMR} (95% Confidence Interval)
GCKR					
Primary omega−3 (2024)	−0.224	0.016	6.56e−45	0.097	
Secondary omega−3 (2022)	−0.258	0.017	4.94e−55	0.055	
ANGPTL3					
Primary omega−3 (2024)	0.197	0.018	1.22e−27	0.898	
Secondary omega−3 (2022)	0.254	0.019	3.85e−40	0.998	
PCSK9					
Primary omega−3 (2024)	0.192	0.020	1.15e−21	0.119	
Secondary omega−3 (2022)	0.107	0.018	4.65e−09	0.750	
TIMD4					
Primary omega−3 (2024)	−0.153	0.021	6.41e−13	0.030	
Secondary omega−3 (2022)	−0.126	0.021	9.51e−10	0.503	
APOB					
Primary omega−3 (2024)	0.488	0.076	1.57e−10	0.153	
Secondary omega−3 (2022)	0.334	0.059	1.74e−08	0.599	

Figure 5 Colocalization of protein QTLs (pQTLs) with genetic loci associated with omega-3 levels. Red dots show the results derived from the primary omega-3 GWAS, and green dots represent the results based on the secondary omega-3 GWAS. SE stands for Standard error.